Filing Flows › Companies › Alnylam Pharmaceuticals › Timeline
Alnylam Pharmaceuticals stock timeline
A year of the price with every insider trade, planned sale, earnings report and material 8-K marked
252 sessions−64.6% to $155.94
Alnylam Pharmaceuticals (ALNY) stock fell 65% over the last 252 sessions, to $155.94. On the way it reported 4 quarters, its insiders filed no open-market trades (10b5-1 plan sales aside) and 1 Form 144 notice of planned sales, and the company filed 4 material 8-Ks. Each is marked on the price and listed with what the stock did next.
Each mark, and what followed
| Date | Kind | What | Next session | 5 sessions | 21 sessions |
|---|---|---|---|---|---|
| Nov 5, 2026 | 8-K | Directors and officers: departures, appointments, pay | −2.8% (+1.7% vs SPY) | — | — |
| Oct 29, 2026 | Earnings | Earnings: beat the EPS estimate by 623.0% | −28.9% (−28.6% vs SPY) | −36.7% (−36.0% vs SPY) | — |
| Oct 2, 2026 | Form 144 | Form 144: Bryan Supran plans to sell $399K | −5.1% (−5.8% vs SPY) | −2.9% (−4.2% vs SPY) | −33.7% (−32.6% vs SPY) |
| Jul 30, 2026 | Earnings | Earnings: missed the EPS estimate by -14.2% | −33.3% (−34.9% vs SPY) | −22.6% (−28.0% vs SPY) | −19.2% (−24.8% vs SPY) |
| May 27, 2026 | 8-K | Directors and officers: departures, appointments, pay | +3.1% (+2.6% vs SPY) | −1.0% (−1.5% vs SPY) | −1.4% (+1.2% vs SPY) |
| Apr 30, 2026 | Earnings | Earnings: beat the EPS estimate by 35.3% | +2.7% (+1.7% vs SPY) | +0.6% (−2.5% vs SPY) | +0.3% (−5.9% vs SPY) |
| Mar 4, 2026 | 8-K | Directors and officers: departures, appointments, pay | −2.1% (−1.5% vs SPY) | −2.1% (−0.8% vs SPY) | −2.6% (+1.5% vs SPY) |
| Feb 12, 2026 | Earnings | Earnings: missed the EPS estimate by -16.5% | −4.4% (−2.8% vs SPY) | +5.2% (+6.2% vs SPY) | −2.8% (+1.6% vs SPY) |
| Dec 3, 2025 | 8-K | Directors and officers: departures, appointments, pay | −1.7% (−1.8% vs SPY) | −15.7% (−16.2% vs SPY) | −17.3% (−18.2% vs SPY) |
What this kind of 8-K usually did
| Item | 8-Ks | Next session, median | Up next session | 21 sessions, median | Typical size |
|---|---|---|---|---|---|
| 5.02 Directors and officers: departures, appointments, pay | 39,174 | −0.1% | 48% | +0.7% | ±1.4% |
Across every company in the move-odds universe, measured from the close before the filing. Every 8-K item ranked →
Report card: every quarter against the estimate → Alnylam Pharmaceuticals: every quarter → Live insider trades →
Prices are daily closes; filings and trades are as filed with the SEC (Form 4 within two business days of the trade, 8-K within four of the event). Moves after a mark are the stock's close-to-close change and the same for SPY; they describe the record, not what the next one will do. Not investment advice.